NEW YORK (GenomeWeb) – Personalized medicine firm Perthera announced a partnership with patient advocacy group Lung Cancer Alliance this week through which it will facilitate molecular testing of lung cancer patients.

The arrangement gives Perthera the opportunity to expand the scope of its molecular profiling work while helping the LCA provide more patients access to such testing.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.